Acomplia Aventis Rimonabant Sanofi

NEW YORK -- A pill that helps you lose weight acomplia aventis rimonabant sanofi and quit smoking? That was amazing enough to capture headlines last week.

The expected green light from Brussels in the next few weeks would mean that the French giant Sanofi-Aventis could begin marketing the treatment, called rimonabant but branded as Acomplia, later this summer. Pi-Sunyer says acomplia aventis rimonabant sanofi the sustained effect is attributable to rimonabant. For example, 63 percent of volunteers getting 20 mg/day for 2 years weighed at least 5 percent less at the end of acomplia aventis rimonabant sanofi the study than they had at its outset.
Neither can be prescribed for any acomplia aventis rimonabant sanofi indications beyond weight loss.

Throughout the study, investigators recorded the volunteers' weight, blood concentrations of cholesterols, and other indicators of metabolic health. Yearlong trials of rimonabant had suggested that the acomplia aventis rimonabant sanofi drug aids initial weight loss. Acomplia pill fell 0. 8% from their baseline value of acomplia aventis rimonabant sanofi 7. 9 %, as compared to a 0. 3% in the placebo group. Roche's Xenical works by blocking the acomplia aventis rimonabant sanofi body's ability to absorb fat. More than 50 percent of the observed reduction in hemoglobin AIc and improvement in HDL levels were calculated to be beyond that attributable to weight loss. We are 99. 9 per cent sure of acomplia aventis rimonabant sanofi approval, a Sanofi spokesman said. The Department of Health says that Acomplia aventis rimonabant sanofi more than half of all British adults -24 million people - are either overweight or obese. Xavier Pi-Sunyer of Columbia University and his colleagues at 64 U. However, we believe regulatory uncertainties will remain. Only 37 and 33 percent of acomplia aventis rimonabant sanofi volunteers getting lower-dose rimonabant and placebo, respectively, achieved comparable weight loss. In anticipation of potential profit, we underline the potential upside to valuation driven by anticipated Phase lib and Phase III trial acomplia aventis rimonabant sanofi results.
It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small market, into a gold mine for the pharmaceutical industry. Other recent studies suggest that rimonabant might break addictions to nicotine, alcohol, and acomplia aventis rimonabant sanofi certain other drugs. In the study's second year, half of each group that had been receiving rimonabant was unknowingly switched to placebos.
Other risks to our price target include clinical trial failure and the non-commercialization of products such as Exubera, Acomplia and Ambien CR.